China National Medical Products Administration Has Approved Marinus Pharmaceuticals' Ganaxolone Oral Suspension For Epileptic Seizures In Patients Two Years Of Age And Older With CDKL5 Deficiency Disorder
Portfolio Pulse from Benzinga Newsdesk
China National Medical Products Administration has approved Marinus Pharmaceuticals' Ganaxolone oral suspension for treating epileptic seizures in patients aged two years and older with CDKL5 deficiency disorder.
July 18, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marinus Pharmaceuticals received approval from the China National Medical Products Administration for its Ganaxolone oral suspension to treat epileptic seizures in patients aged two years and older with CDKL5 deficiency disorder.
The approval of Ganaxolone in China opens a significant new market for Marinus Pharmaceuticals, likely boosting its revenue and market presence. This positive regulatory news is expected to drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100